Coulter Partners Top hires for VC & PE portfolio companies Q1-2024
Search Highlights
Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.
This quarter’s successful placements include:
Function | Focus area | Location |
CEO | Therapeutic devices | Austria |
Chief Business Officer | Precision biologics | US |
Chief Financial Officer | Remote monitoring | France |
Chief Strategy Officer | Medical devices | Israel |
Chief Medical Officer | Radiopharmaceuticals | US |
Chief of Staff | Vaccines | Denmark |
VP Global Program Leader, Respiratory | Multi-modality biotech | UK |
VP Technology & Product Development | DNA technology | UK |
Controller | Contract manufacturing | US |
Senior Director Pharmaceutical Development | Drug delivery | Ireland |
Director Market Access & Pricing Global | Ophthalmology | Italy |
Investment Manager Digital Health | Life sciences investor | Netherlands |
General Manager Infectious Diseases | Biocluster | France |
Board Director | Personalized digital health | Switzerland |
Board Director | Electronic medical instrumentation | US |
Board Director | Immunotherapies | Sweden |
Newly opened projects include:
Function | Focus area | Location |
CEO | Medical devices | Belgium |
CEO | Precision medicines | US |
Chief Commercial Officer | Contract research organization (CRO) | UK |
Chief Development Officer | Protein degradation | DACH |
Chief Scientific Officer | Small molecules | Spain |
Chief Financial Officer | Gene therapy | US |
Chief Operating Officer | Incubator/ tech transfer | UK |
Head of Strategy & Commercial Excellence | Drug delivery systems | Germany |
SVP, Head of Business Development | Drug discovery services | Germany |
VP of Science | Precision nutrition | UK |
VP, Head of Translational Development | Gene editing | Spain |
VP Research & Preclinical | Synthetic biology | UK |
VP Business Development | tRNA technologies | US |
Life Sciences Partner | Life sciences investor | Italy |
Board Director | T-cell therapies | US/ Europe |
